Aptorum Group Limited - Class A Ordinary Shares (APM)
1.8500
+0.00 (0.00%)
NASDAQ · Last Trade: Sep 12th, 5:03 AM EDT
Detailed Quote
Previous Close
1.850
Open
-
Bid
1.910
Ask
2.110
Day's Range
N/A - N/A
52 Week Range
0.4600 - 4.800
Volume
3,027
Market Cap
7.12M
PE Ratio (TTM)
-2.372
EPS (TTM)
-0.8
Dividend & Yield
N/A (N/A)
1 Month Average Volume
19,200,771
Chart
About Aptorum Group Limited - Class A Ordinary Shares (APM)
Aptorum Group Ltd is a biotechnology and pharmaceutical company focused on developing innovative therapeutic solutions to address significant unmet medical needs. The company is involved in the discovery and commercialization of new drugs, particularly in the areas of metabolic diseases, infectious diseases, and other major health challenges. Aptorum Group is dedicated to advancing its proprietary drug candidates through various stages of development, including preclinical and clinical trials, while also exploring strategic partnerships and collaborations to enhance its research capabilities and market reach. Read More
As the regular session of the US market concludes on Wednesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced a joint presentation at the H.C. Wainwright 27th Annual Global Investment Conference (https://hcwevents.com/annualconference/).
Stay up-to-date with the latest market trends one hour before the close of the markets on Friday. Explore the top gainers and losers during today's session in our detailed report.
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Aptorum Group Limited (NASDAQ: APM) shares dropped 33.18% in Friday's pre-market trading after soaring 234.65% the previous session, driven by DiamiR's test approval and merger news, with trading volume far above average.
As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Aug. 21, 2025 (GLOBE NEWSWIRE) -- DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, today announced that DiamiR received a Clinical Laboratory Evaluation Program (CLEP) Test Approval for its APOE Genotyping test from the New York State Department of Health (NYSDOH). This milestone allows DiamiR to offer its validated APOE Genotyping molecular testing in a variety of biological samples, such as blood, buccal swab, saliva, and tissue, through its Clinical Laboratory Improvement Amendments (CLIA) certified, College of American Pathologists (CAP) accredited clinical laboratory by licensed healthcare providers in New York State and nationwide.
